Attempts to inhibit BCR activity in DLBCL (and related B-cell tumors) with SYK and PI3K inhibitors have been characterized by limited activity and excessive toxicity [15,42,43,44,45]. The gene discussed is BCR; the disease is diffuse large B-cell lymphoma.